Structure, mechanism and therapeutic utility of immunosuppressive oligonucleotides
dc.citation.epage | 225 | en_US |
dc.citation.spage | 216 | en_US |
dc.citation.volumeNumber | 105 | en_US |
dc.contributor.author | Bayik D. | en_US |
dc.contributor.author | Gursel, I. | en_US |
dc.contributor.author | Klinman, D. M. | en_US |
dc.date.accessioned | 2018-04-12T10:53:24Z | |
dc.date.available | 2018-04-12T10:53:24Z | |
dc.date.issued | 2016 | en_US |
dc.department | Department of Molecular Biology and Genetics | en_US |
dc.description.abstract | Synthetic oligodeoxynucleotides that can down-regulate cellular elements of the immune system have been developed and are being widely studied in preclinical models. These agents vary in sequence, mechanism of action, and cellular target(s) but share the ability to suppress a plethora of inflammatory responses. This work reviews the types of immunosuppressive oligodeoxynucleotide (Sup ODN) and compares their therapeutic activity against diseases characterized by pathologic levels of immune stimulation ranging from autoimmunity to septic shock to cancer (see graphical abstract). The mechanism(s) underlying the efficacy of Sup ODN and the influence size, sequence and nucleotide backbone on function are considered. © Published by Elsevier Ltd. | en_US |
dc.description.provenance | Made available in DSpace on 2018-04-12T10:53:24Z (GMT). No. of bitstreams: 1 bilkent-research-paper.pdf: 179475 bytes, checksum: ea0bedeb05ac9ccfb983c327e155f0c2 (MD5) Previous issue date: 2016 | en |
dc.identifier.doi | 10.1016/j.phrs.2015.11.010 | en_US |
dc.identifier.issn | 1043-6618 | |
dc.identifier.uri | http://hdl.handle.net/11693/36789 | |
dc.language.iso | English | en_US |
dc.publisher | Academic Press | en_US |
dc.relation.isversionof | http://dx.doi.org/10.1016/j.phrs.2015.11.010 | en_US |
dc.source.title | Pharmacological Research | en_US |
dc.subject | CpG oligonucleotide | en_US |
dc.subject | Dendritic cell | en_US |
dc.subject | IRF5 | en_US |
dc.subject | IRF8 | en_US |
dc.subject | TLR9 | en_US |
dc.subject | a 151 | en_US |
dc.subject | CpG oligodeoxynucleotide | en_US |
dc.subject | Quanine oligodeoxynucleotide | en_US |
dc.subject | h 154 | en_US |
dc.subject | Inhibitory oligodeoxynucleotide | en_US |
dc.subject | Microsatellite oligodeoxynucleotide | en_US |
dc.subject | Oligonucleotide | en_US |
dc.subject | STAT protein | en_US |
dc.subject | Suppressive oligodeoxynucleotide | en_US |
dc.subject | Synthetic oligonucleotide | en_US |
dc.subject | Toll like receptor 4 | en_US |
dc.subject | Toll like receptor 7 | en_US |
dc.subject | Toll like receptor 9 | en_US |
dc.subject | Unclassified drug | en_US |
dc.title | Structure, mechanism and therapeutic utility of immunosuppressive oligonucleotides | en_US |
dc.type | Article | en_US |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- Structure, mechanism and therapeutic utility of immunosuppressive oligonucleotides.pdf
- Size:
- 1.33 MB
- Format:
- Adobe Portable Document Format
- Description:
- Full printable version